Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma

Biochemical Pharmacology

Volumn 85, Issue 3, 2013, Pages 356-366

  Yu, Hui Chuan ^a   Chen, Hui Ju ^a   Chang, Ya Ling ^a,d   Liu, Chun Yu ^b,c   Shiau, Chung Wai ^c   Cheng, Ann Lii ^a   Chen, Kuen Feng ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Apoptosis; CIP2A; Erlotinib; HCC; PP2A

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ERLOTINIB; FORSKOLIN; OKADAIC ACID; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN KINASE B; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DOWN REGULATION; DRUG INHIBITION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN CELL CULTURE; IMMUNOPRECIPITATION; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; AUTOANTIGENS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; LIVER NEOPLASMS; MALE; MEMBRANE PROTEINS; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; PROTEIN KINASE INHIBITORS; PROTEIN PHOSPHATASE 2; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RNA, SMALL INTERFERING;

EID: 84872682401     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2012.11.009     Document Type: Article

References (50)

1. Verslype C, Van Cutsem E, Dicato M, Arber N, Berlin JD, Cunningham D, et al. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. Ann Oncol 2009;20 Suppl 7:vii1-vii6.
2. S. Tanaka, and S. Arii Molecularly targeted therapy for hepatocellular carcinoma Cancer Sci 100 2009 1 8
3. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, and J.F. Blanc Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
4. A.L. Cheng, Y.K. Kang, Z. Chen, C.J. Tsao, S. Qin, and J.S. Kim Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 2009 25 34
5. C. Berasain, J. Castillo, J. Prieto, and M.A. Avila New molecular targets for hepatocellular carcinoma: the ErbB1 signaling system Liver Int 27 2007 174 185
6. J.B. Gibbs Anticancer drug targets: growth factors and growth factor signaling J Clin Invest 105 2000 9 13
7. P.A. Philip, M.R. Mahoney, C. Allmer, J. Thomas, H.C. Pitot, and G. Kim Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer J Clin Oncol 23 2005 6657 6663
8. C. Berasain, M.J. Perugorria, M.U. Latasa, J. Castillo, S. Goni, and M. Santamaria The epidermal growth factor receptor: a link between inflammation and liver cancer Exp Biol Med (Maywood) 234 2009 713 725
9. S. Whittaker, R. Marais, and A.X. Zhu The role of signaling pathways in the development and treatment of hepatocellular carcinoma Oncogene 29 2010 4989 5005
10. J.M. Llovet, and J. Bruix Molecular targeted therapies in hepatocellular carcinoma Hepatology 48 2008 1312 1327
11. Y. Ito, T. Takeda, M. Sakon, M. Tsujimoto, S. Higashiyama, and K. Noda Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma Br J Cancer 84 2001 1377 1383
12. S. Kira, T. Nakanishi, S. Suemori, M. Kitamoto, Y. Watanabe, and G. Kajiyama Expression of transforming growth factor alpha and epidermal growth factor receptor in human hepatocellular carcinoma Liver 17 1997 177 182
13. J. Mendelsohn, and J. Baselga The EGF receptor family as targets for cancer therapy Oncogene 19 2000 6550 6565
14. C.M. Rocha-Lima, H.P. Soares, L.E. Raez, and R. Singal EGFR targeting of solid tumors Cancer Control 14 2007 295 304
15. A. Huether, M. Hopfner, A.P. Sutter, D. Schuppan, and H. Scherubl Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics J Hepatol 43 2005 661 669
16. J.D. Moyer, E.G. Barbacci, K.K. Iwata, L. Arnold, B. Boman, and A. Cunningham Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase Cancer Res 57 1997 4838 4848
17. Ling YH, Li T, Yuan Z, Haigentz M, Jr., Weber TK, Perez-Soler R. Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1/S phase arrest in human non-small-cell lung cancer cell lines. Mol Pharmacol 2007; 72:248-58.
18. Y.H. Ling, R. Lin, and R. Perez-Soler Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptorL858R mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAK Mol Pharmacol 74 2008 793 806
19. M.B. Thomas, R. Chadha, K. Glover, X. Wang, J. Morris, and T. Brown Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma Cancer 110 2007 1059 1067
20. M. Ono, and M. Kuwano Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs Clin Cancer Res 12 2006 7242 7251
21. L.V. Sequist, D.W. Bell, T.J. Lynch, and D.A. Haber Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer J Clin Oncol 25 2007 587 595
22. T. John, G. Liu, and M.S. Tsao Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors Oncogene 28 Suppl. 1 2009 S14 S23
23. S.C. Lee, S.G. Lim, R. Soo, W.S. Hsieh, J.Y. Guo, and T. Putti Lack of somatic mutations in EGFR tyrosine kinase domain in hepatocellular and nasopharyngeal carcinoma Pharmacogenet Genomics 16 2006 73 74
24. M.C. Su, H.C. Lien, and Y.M. Jeng Absence of epidermal growth factor receptor exon 18-21 mutation in hepatocellular carcinoma Cancer Lett 224 2005 117 121
25. M. Kudo Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma Dig Dis 29 2011 289 302
26. K.J. Schmitz, J. Wohlschlaeger, H. Lang, G.C. Sotiropoulos, M. Malago, and K. Steveling Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection J Hepatol 48 2008 83 90
27. K.F. Chen, P.Y. Yeh, K.H. Yeh, Y.S. Lu, S.Y. Huang, and A.L. Cheng Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells Cancer Res 68 2008 6698 6707
28. P.J. Eichhorn, M.P. Creyghton, and R. Bernards Protein phosphatase 2A regulatory subunits and cancer Biochim Biophys Acta 1795 2009 1 15
29. C. Van Hoof, and J. Goris Phosphatases in apoptosis: to be or not to be, PP2A is in the heart of the question Biochim Biophys Acta 1640 2003 97 104
30. D. Perrotti, and P. Neviani Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias Cancer Metastasis Rev 27 2008 159 168
31. K.F. Chen, P.Y. Yeh, C. Hsu, C.H. Hsu, Y.S. Lu, and H.P. Hsieh Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway J Biol Chem 284 2009 11121 11133
32. P. Neviani, R. Santhanam, R. Trotta, M. Notari, B.W. Blaser, and S. Liu The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein Cancer Cell 8 2005 355 368
33. M.R. Junttila, S.P. Li, and J. Westermarck Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival FASEB J 22 2008 954 965
34. M.R. Junttila, P. Puustinen, M. Niemela, R. Ahola, H. Arnold, and T. Bottzauw CIP2A inhibits PP2A in human malignancies Cell 130 2007 51 62
35. J. Katz, A. Jakymiw, M.K. Ducksworth, C.M. Stewart, I. Bhattacharyya, and S. Cha CIP2A expression and localization in oral carcinoma and dysplasia Cancer Biol Ther 10 2010 694 699
36. C. Come, A. Laine, M. Chanrion, H. Edgren, E. Mattila, and X. Liu CIP2A is associated with human breast cancer aggressivity Clin Cancer Res 15 2009 5092 5100
37. Q.Z. Dong, Y. Wang, X.J. Dong, Z.X. Li, Z.P. Tang, and Q.Z. Cui CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis Ann Surg Oncol 18 2011 857 865
38. A. Khanna, C. Bockelman, A. Hemmes, M.R. Junttila, J.P. Wiksten, and M. Lundin MYC-dependent regulation and prognostic role of CIP2A in gastric cancer J Natl Cancer Inst 101 2009 793 805
39. W. Qu, W. Li, L. Wei, L. Xing, X. Wang, and J. Yu CIP2A is overexpressed in esophageal squamous cell carcinoma Med Oncol 2010
40. M.H. Vaarala, M.R. Vaisanen, and A.C.I.P2A. Ristimaki expression is increased in prostate cancer J Exp Clin Cancer Res 29 2010 136
41. J. Wang, W. Li, L. Li, X. Yu, J. Jia, and C. Chen CIP2A is over-expressed in acute myeloid leukaemia and associated with HL60 cells proliferation and differentiation Int J Lab Hematol 33 2011 290 298
42. K.F. Chen, C.Y. Liu, Y.C. Lin, H.C. Yu, T.H. Liu, and D.R. Hou CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells Oncogene 29 2010 6257 6266
43. A. Khanna, J. Okkeri, T. Bilgen, T. Tiirikka, M. Vihinen, and T. Visakorpi ETS1 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells PLoS ONE 6 2011 e17979
44. L.N. Johnson Protein kinase inhibitors: contributions from structure to clinical compounds Q Rev Biophys 42 2009 1 40
45. K.F. Chen, H.C. Yu, C.Y. Liu, H.J. Chen, Y.C. Chen, and D.R. Hou Bortezomib sensitizes HCC cells to CS-1008, an antihuman death receptor 5 antibody, through the inhibition of CIP2A Mol Cancer Ther 10 2011 892 901
46. Y.A. Choi, J.S. Park, M.Y. Park, K.S. Oh, M.S. Lee, and J.S. Lim Increase in CIP2A expression is associated with doxorubicin resistance FEBS Lett 585 2011 755 760
47. L. Ma, Z.S. Wen, Z. Liu, Z. Hu, J. Ma, and X.Q. Chen Overexpression and small molecule-triggered downregulation of CIP2A in lung cancer PLoS ONE 6 2011 e20159
48. N. Yamamoto, M. Honma, and H. Suzuki Off-target STK10 inhibition by erlotinib enhances lymphocytic activity leading to severe skin disorders Mol Pharmacol 2011
49. S. Boehrer, L. Ades, T. Braun, L. Galluzzi, J. Grosjean, and C. Fabre Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study Blood 111 2008 2170 2180
50. Z. Li, M. Xu, S. Xing, W.T. Ho, T. Ishii, and Q. Li Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth J Biol Chem 282 2007 3428 3432